Idiopathic Pulmonary Fibrosis (IPF) Clinical Trial
Official title:
Pilot Study to Evaluate Inhaled N-Acetylcysteine in Pulmonary Fibrosis
This study plans to learn more about the safety and tolerability of inhaled N-Acetylcysteine (NAC) in patients with pulmonary fibrosis. The study will also create a bank of data, blood, and sputum from IPF patients for future research.
This study plans to learn more about the safety and tolerability of inhaled N-Acetylcysteine (NAC) in patients with pulmonary fibrosis. The study will also create a bank of data, blood, and sputum from IPF patients for future research. NAC is a medication used to loosen thick mucus. NAC was initially licensed for use in 1968. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system, and it is available as a generic medication and is not very expensive. Inhaled NAC has been used as a mucus-dissolving therapy in respiratory conditions with excessive and/or thick mucus production. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT04497831 -
Morphine for Dyspnea in Pulmonary Fibrosis
|
Phase 3 | |
| Recruiting |
NCT05119972 -
Tolerability, Pharmacokinetics and Efficacy of ZSP1603 in Patients With Idiopathic Pulmonary Fibrosis （IPF）
|
Phase 1/Phase 2 | |
| Completed |
NCT01718990 -
Biomarker Discovery for Novel Drug Development in Idiopathic Pulmonary Fibrosis
|
||
| Completed |
NCT00162760 -
Treatment of Idiopathic Pulmonary Fibrosis With Thalidomide
|
Phase 2 | |
| Terminated |
NCT04589260 -
TD-1058 First-In-Human Study in Healthy Subjects and Subjects With Idiopathic Pulmonary Fibrosis
|
Phase 1 | |
| Completed |
NCT04069143 -
A Study to Evaluate the Safety, Tolerability, Kinetics and Repeatability of 18F-BMS-986327
|
Phase 1 | |
| Completed |
NCT03050255 -
Short-term Effects of Supplemental Oxygen in Patients With IPF
|
N/A | |
| Terminated |
NCT02013700 -
Allogeneic Human Cells (hMSC)in Patients With Idiopathic Pulmonary Fibrosis Via Intravenous Delivery (AETHER)
|
Phase 1 | |
| Active, not recruiting |
NCT04598919 -
Saracatinib in the Treatment of Idiopathic Pulmonary Fibrosis
|
Phase 1/Phase 2 | |
| Completed |
NCT03981094 -
A Study of the Pharmacokinetic Interaction Between Pirfenidone and BMS-986278 in Healthy Participants
|
Phase 1 | |
| Completed |
NCT02758808 -
Pulmonary Fibrosis Foundation Patient Registry
|
||
| Not yet recruiting |
NCT05387785 -
Study to Assess the Safety and Tolerability of ANG-3070 in Subjects With Idiopathic Pulmonary Fibrosis
|
Phase 1 | |
| Active, not recruiting |
NCT05938920 -
Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)
|
Phase 2 | |
| Completed |
NCT02538536 -
A Phase 2 Study to Evaluate the Safety and Tolerability of PBI-4050 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
|
Phase 2 | |
| Completed |
NCT01371305 -
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
|
Phase 2 | |
| Recruiting |
NCT03478553 -
The Genetics of Pulmonary Fibrosis
|
||
| Recruiting |
NCT05975983 -
Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis
|
Phase 2 | |
| Completed |
NCT03650075 -
To Determine Safety and Tolerability of MG-S-2525 and to Evaluate Its PK Profile in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT03832946 -
A Study to Test the Efficacy and Safety of Inhaled GB0139 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
|
Phase 2 | |
| Completed |
NCT02874989 -
Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis: a Human Trial
|
Phase 1 |